<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603824</url>
  </required_header>
  <id_info>
    <org_study_id>MHIRB # 2007-058</org_study_id>
    <nct_id>NCT00603824</nct_id>
  </id_info>
  <brief_title>Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)</brief_title>
  <official_title>Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Methodist Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and efficacy of fondaparinux in patients with
      heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with
      HIT who are treated with fondaparinux experience a prompt and complete recovery of their
      platelet count, and the secondary objective is to determine if any new blood clots are formed
      while receiving the fondaparinux and up to one month after study enrollment. This information
      will be compared to a historical control.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI relocated
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet count recovery</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent thromboembolic complications</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heparin-Induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fondaparinux</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Direct thrombin inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux</intervention_name>
    <description>fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if &gt;100 kg</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>argatroban or lepirudin</intervention_name>
    <description>continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Refludan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age;

          -  If female of childbearing potential, negative pregnancy test result;

          -  Diagnosis of HIT confirmed by the following: Decreased platelet count by 50% or
             greater OR platelets &lt; 100,000/mm3 during or within 2 weeks after heparin exposure
             and/or new thromboembolic complications during or within 2 weeks after heparin
             exposure;

          -  Laboratory confirmation (either heparin PF4 antibody or serotonin release assay
             positive).

        Exclusion Criteria:

          -  Estimated creatinine clearance less than 30 ml/min (either measured or by using
             Cockcroft Gault equation);

          -  Pregnancy or lactating;

          -  Blood dyscrasia other than HIT;

          -  History of thrombocytopenia associated with fondaparinux;

          -  Recent (within 6 weeks) or planned surgery of CNS, eye or traumatic surgery resulting
             in large open surfaces or other procedures with high bleeding risk or if lumbar
             puncture is planned;

          -  Active bleeding of GI tract, GU tract, CNS or respiratory tract;

          -  Malignant hypertension, pericarditis, pericardial effusion, endocarditis or eclampsia;

          -  Inadequate laboratory facilities, inadequate support system at home, alcoholism, drug
             abuse, psychosis or dementia;

          -  Hypersensitivity or contraindication to warfarin or fondaparinux.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bob L Lobo, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sohail Minhas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <name_title>Bob Lobo, Program Director, Clinical Pharmacy</name_title>
    <organization>Vanderbilt University</organization>
  </responsible_party>
  <keyword>heparin-Induced thrombocytopenia</keyword>
  <keyword>fondaparinux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Lepirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

